A pioneer in the field of contrast agents
with almost 90 years of experience, Guerbet is the only pharmaceutical group fully dedicated to medical imaging worldwide
. As such it has a complete offering of contrast agents for X-ray
and interventional radiology
, along with a range of injectors
and related medical devices
to provide improved patient diagnosis and treatment.
To promote the discovery of new products and ensure its future growth, Guerbet devotes significant resources to research and development every year (approximately 9% of sales). Guerbet (GBT) is listed on NYSE Euronext Paris (Eurolist Compartment B – Mid Caps) and had sales of €409 million in 2014 with a total workforce of 1,461 employees
On July 27th 2015, Guerbet announced that it has entered into a definitive agreement under which it will acquire Mallinckrodt’s contrast media and delivery systems business (“CMDS”).